Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Int J Immunopathol Pharmacol
Prif Awduron: Steinhardt, Maximilian Johannes, Zhou, Xiang, Krummenast, Franziska, Meckel, Katharina, Nickel, Katharina, Böckle, David, Messerschmidt, Janin, Knorz, Sebastian, Dierks, Alexander, Heidemeier, Anke, Lapa, Constantin, Einsele, Hermann, Rasche, Leo, Kortüm, Klaus Martin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: SAGE Publications 2020
Pynciau:
Case Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768838/
https://ncbi.nlm.nih.gov/pubmed/33353443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2058738420980258
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg